Related Experiment Video

Updated: Jun 2, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

[Tyrosine kinase inhibitors in oncology]

T Zander1, M Hallek

  • 1Centrum für Integrierte Onkologie Köln-Bonn, Klinik I für Innere Medizin, Universitätsklinik Köln, Kerpenerstrasse 62, Köln, Germany. thomas.zander@uk-koeln.de

Der Internist
|April 20, 2011
PubMed

Insights

Tyrosine kinase inhibitors offer significant clinical benefits for certain cancer patients by targeting key cell growth pathways. Continued research and diagnostics are vital for developing these important oncology drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Tyrosine kinase inhibitors (TKIs) represent a novel class of targeted cancer therapies.
  • Their clinical significance is rapidly growing due to substantial, durable patient benefits.
  • Tumor cell growth and survival critically depend on tyrosine kinase activity.

Purpose:

  • To highlight the importance of tyrosine kinase inhibitors in oncology.
  • To underscore the molecular basis for their efficacy in specific cancer types.
  • To emphasize the need for integrated research and diagnostics for future TKI development.

Summary:

  • Tyrosine kinase inhibitors are increasingly vital in oncology, offering major clinical benefits to specific patient groups.
  • Their success stems from targeting essential tyrosine kinases for tumor cell proliferation and survival, exemplified by BCR-ABL in CML and EGFR mutations in lung adenocarcinoma.
  • Future development hinges on strong collaboration between clinical trials, preclinical research, and molecular diagnostics.

Impact:

  • Accelerates the development of targeted cancer therapies.
  • Improves patient outcomes through precision medicine approaches.
  • Establishes a framework for identifying and treating other oncogene-dependent tumors.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...